Статья
Роль тромбоцитов в патогенезе атеросклероза
Участие тромбоцитов в развитии атеротромбоза при острых формах сердечно-сосудистых заболеваний общепризнано и достаточно хорошо исследовано, в то время как их значение в патогенезе атеросклероза сосудов, начиная с самых ранних стадий, требует дальнейшего изучения. В настоящей статье проведен анализ роли тромбоцитов в патогенезе атеросклероза. Рассмотрены современные взгляды на патогенез атеросклероза, тромбоцитарно-эндотелиальные взаимодействия, молекулярные механизмы активации тромбоцитов, иммунная функция тромбоцитов с точки зрения начальных стадий атерогенеза, исследования эффекта антитромбоцитарной терапии в первичной и вторичной профилактике атеросклероза. Обозначена ведущая роль тромбоцитов в воспалительных и иммунных реакциях организма человека, которая реализуется за счет комплекса иммунных рецепторов, молекул адгезии и медиаторов.
1. Здравоохранение в России. 2019: Стат. сб. / Росстат. М.: З-46, 2019. С. 170. https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2019.pdf
2. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2019 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2020. С. 299.
3. Кухарчук В.В., Ежов М.В., Сергиенко И.В., Арабидзе Г.Г., Бубнова М.Г., Балахонова Т.В., Гуревич В. С., Качковский М.А., Коновалов Г. А., Константинов В.О., Малышев П.П., Покровский С.Д., Соколов А.А., Сумароков А.Б., Горнякова Д.Б., Обрезан А.Г., Шапошник И.И., Анциферов М.Б., Аншелес А.А., Аронов Д.М, Ахмеджанов Н.М., Барбараш О.Л., Бойцов С.А., Воевода М.И., Галстян Г.Р., Галявич А.С., Драпкина О.М., Дупляков Д.В., Ерёгин С.Я., Карпов Р.С., Карпов Ю.А., Козиолова Н.А., Космачёв Е.Д., Небиеридзе Д.В., Недогода С.В., Олейников В.Э., Рагино Ю.И., Скибицкий В.В., Смоленская О.Г., Филиппов А.Е., Халимов Ю.Ш., Чазова И.Е., Шестакова М.В., Якушин С.С. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии, 2020; 1. URL: https://cyberleninka.ru/article/n/diagnostika-i-korrektsiya-narusheniylipidnogo-obmena-s-tselyu-profilaktiki-i-lecheniyaateroskleroza-rossiyskie-rekomendatsii-vii (дата обращения: 04.07.2021).
4. European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Atherosclerosis, 2016; 2016: 207–274.
5. Vasil’ev S.A., Melkumyan A.L., Berkovskij A.L., Suvorov A.V., Mazurov A.V., Kozlov A.A. Kliniko-laboratornaya diagnostika narushenij funkcij trombocitov. Metodicheskoe rukovodstvo. Moskva, 2013, 76 p. ISBN: 978-5-906548-07-8. (In Russ.)
6. Jackson S.P. Arterial thrombosis-insidious, unpredictable and deadly. Nat Med., 2011 Nov 7; 17 (11): 1423–1436. doi: 10.1038/nm.2515. PMID: 22064432
7. Badimon L., Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J. Intern. Med., 2014 Dec; 276: 618–632.
8. Wu M.D., Atkinson T.M., Lindner J.R. Platelets and von Willebrand factor in atherogenesis. Blood, 2017 Mar 16; 129 (11): 1415–1419. doi: 10.1182/blood-2016-07-692673. Epub 2017 Feb 7. PMID: 28174163; PMCID: PMC5356449.
9. Gawaz M. Platelets in the onset of atherosclerosis. Blood Cells Mol. Dis., 2006 Mar-Apr; 36 (2): 206–210. doi: 10.1016/j.bcmd.2005.12.022. Epub 2006 Feb 13. PMID: 16476558
10. Massberg S., Brand K., Grьner S. et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J. Exp. Med., 2002; 196: 887–896. doi: 10.1084/jem.20012044
11. Nording H.M., Seizer P., Langer H.F. Platelets in inflammation and atherogenesis. Front Immunol., 2015; 6: 98. doi: 10.3389/fimmu.2015.00098
12. Hawrylowicz C.M., Howells G.L., Feldmann M.; Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production. J. Exp. Med., 1 October 1991; 174 (4): 785–790. doi: https://doi.org/10.1084/jem.174.4.785
13. Huo Y., Schober A., Forlow S.B., Smith D.F., Hyman M.C., Jung S., Littman D.R., Weber C., Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat. Med., 2003 Jan; 9 (1): 61–67. doi: 10.1038/nm810. Epub 2002 Dec 16. PMID: 12483207.
14. Guidelines on myocardial revascularization / The Task Force on Myocardial Revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery, W. Wijns, Ph. Kolh, N. Danchin et al. Eur. Heart J., 2010; 31: 2501–2555.
15. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation / The Task Force on the management of STsegment elevation acute myocardial infarction of the European Society of Cardiology. F. Van de Werf, J. Bax, A. Betriu et al. Eur. Heart J., 2008; 28: 2909–2945.
16. Naghavi M., Libby P., Falk E. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation., 2003; 108: 1664–1672.
17. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N. Engl. J. Med., 1992 Jan 23; 326 (4): 242–250. doi: 10.1056/NEJM199201233260406. PMID: 1727977.
18. Ross R., Glomset J.A. The pathogenesis of atherosclerosis (first of two parts). N. Engl. J. Med., 1976; 295: 369–377; Item (second of two parts), 420–425.
19. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med., 1999 Jan 14; 340 (2): 115–126. doi: 10.1056/NEJM199901143400207. PMID: 9887164.
20. Kim H., Conway E.M. Platelets and Complement Cross-Talk in Early Atherogenesis. Front Cardiovasc. Med., 2019 Sep 6; 6: 131. doi: 10.3389/fcvm.2019.00131. PMID: 31555668; PMCID: PMC6742699.
21. Santos-Gallego C.G., Picatoste B., Badimуn J.J., Pathophysiology of acute coronary syndrome. Curr. Atheroscler. Rep., 2014; 16: 1–9. doi: 10.1007/s11883-014-0401-9
22. Projahn D., Koenen R.R. Platelets: key players in vascular inflammation. J. Leukoc. Biol., 2012; 92: 1167–1175. doi: 10.1189/jlb.0312151
23. Abedinzadeh N., Pedram B., Sadeghian Y. et al. A histopathological analysis of the epidemiology of coronary atherosclerosis: an autopsy study. Diagn. Pathol., 2015; 10: 87. doi: 10.1186/s13000-015-0324-y
24. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med., 2005 Apr 21; 352 (16): 1685–1695. doi: 10.1056/NEJMra043430. PMID: 15843671.
25. Libby P., Ridker P.M., Hansson G.K. Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol., 2009 Dec 1; 54 (23): 2129–2138. doi: 10.1016/j.jacc.2009.09.009. PMID: 19942084; PMCID: PMC2834169.
26. Alekperov E.Z., Nadzhafov R.N. Sovremennye koncepcii o roli vospaleniya pri ateroskleroze. Kardiologiya, 2010; 6 (50): 88–91. (In Russ.)
27. Shchelkunova T.A., Morozov I.A., Rubcov P.M., Samohodskaya L.M., Sobenin I.A., Orekhov A.N., Smirnov A.N. Koordinaciya ekspressii genov v hode aterogeneza. Biohimiya, 2013; 8 (78): 1187–1200. (In Russ.)
28. Lihoded V.G., Bondarenko V.M., Gincburg A.L. Ekzogennye i endogennye faktory v patogeneze ateroskleroza. Receptornaya teoriya aterogeneza. Rossijskij kardiologicheskij zhurnal, 2010; 2 (82): 92–96. (In Russ.)
29. Nazarenko M.S., Markov A.V., Slepcov A.A. Sovremennye predstavleniya o molekulyarno-geneticheskih mekhanizmah aterogeneza. Molekulyarno-geneticheskie tekhnologii v medicinskoj praktike. Novosibirsk, 2015. 56–68. (In Russ.)
30. Makarov S.S. NF-kappaB as a therapeutic target in chronic inflammation: recent advances. Mol. Med. Today, 2000; 11 (6): 441–448.
31. Корякина Л.Б., Пивоваров Ю.И., Курильская Т.Е., Сергеева А.С., Бабушкина И.В. Дисфункция сосудистого эндотелия при артериальной гипертонии и ишемической болезни сердца (обзор литературы). Acta Biomed. Sci., 2013; 2 (1): 165–170.
32. Koryakina L.B., Pivovarov Yu.I., Kuril’skaya T.E., Sergeeva A.S., Babushkina I.V. Disfunkciya sosudistogo endoteliya pri arterial’noj gipertonii i ishemicheskoj bolezni serdca (obzor literatury). Acta Biomedica Scientifica. 2013; 2 (1): 165–170. (In Russ.)
33. Hadi H.A., Carr C.S., Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc. Health. Risk Manag., 2005; 1 (3): 183–98. PMID: 17319104; PMCID: PMC1993955.
34. Bornfeldt K.E., Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab., 2011 Nov 2; 14 (5): 575–585. doi: 10.1016/j.cmet.2011.07.015. PMID: 22055501; PMCID: PMC3217209.
35. Gimbrone M.A.Jr., Garcнa-Cardeсa G. Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. Cardiovasc Pathol., 2013 Jan-Feb; 22 (1): 9–15. doi: 10.1016/j.carpath.2012.06.006. Epub 2012 Jul 18. PMID: 22818581; PMCID: PMC4564111.
36. Tabas I., Williams K.J., Borйn J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation, 2007 Oct 16; 116 (16): 1832–1844. doi: 10.1161/CIRCULATIONAHA.106.676890. PMID: 17938300.
37. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med., 2006 Feb 9; 354 (6): 610–621. doi: 10.1056/NEJMra052723. PMID: 16467548.
38. Mestas J., Ley K. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc. Med., 2008 Aug; 18 (6): 228–232. doi: 10.1016/j.tcm.2008.11.004. PMID: 19185814; PMCID: PMC2650852.3.
39. Arabidze G.G. Klinicheskaya immunologiya ateroskleroza ot teorii k praktike. Ateroskleroz i dislipidemii, 2013; 1 (10): 4–19. URL: https://cyberleninka.ru/article/n/klinicheskaya-immunologiya-aterosklerozaot-teorii-k-praktike. (In Russ.)
40. Galkina E., Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev. Immunol., 2009; 27: 165–197. doi: 10.1146/annurev.immunol.021908.132620. PMID: 19302038; PMCID: PMC2734407.
41. Rossaint J., Herter J.M., van Aken H., Napirei M., Dцring Y., Weber C., Soehnlein O., Zarbock A. Synchronized integrin engagement and chemokine activation is crucial in neutrophil extracellular trapmediated sterile inflammation. Blood., 2014 Apr 17; 123 (16): 2573–2584. doi: 10.1182/blood-2013-07-516484. Epub 2013 Dec 12. PMID: 24335230.
42. Koenen R.R., von Hundelshausen P., Nesmelova I.V., Zernecke A., Liehn E.A., Sarabi A., Kramp B.K., Piccinini A.M., Paludan S.R., Kowalska M.A., Kungl A.J., Hackeng T.M., Mayo K.H., Weber C. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat. Med., 2009 Jan; 15 (1): 97–103. doi: 10.1038/nm.1898. Epub 2009 Jan 4. PMID: 19122657.
43. StrьЯmann T., Tillmann S., Wirtz T., Bucala R., von Hundelshausen P., Bernhagen J. Platelets are a previously unrecognised source of MIF. Thromb. Haemost., 2013 Nov; 110 (5): 1004–1013. doi: 10.1160/TH13-01-0049. Epub 2013 Jul 11. PMID: 23846621.
44. Daub K., Seizer P., Stellos K., Krдmer B.F., Bigalke B., Schaller M., Fateh-Moghadam S., Gawaz M., Lindemann S. Oxidized LDL-activated platelets induce vascular inflammation. Semin. Thromb. Hemost., 2010 Mar; 36 (2): 146–156. doi: 10.1055/s-0030-1251498. Epub 2010 Apr 22. PMID: 20414829.
45. Burger P.C., Wagner D.D. Platelet P-selectin facilitates atherosclerotic lesion development. Blood., 2003 Apr 1; 101 (7): 2661–2666. doi: 10.1182/blood-2002-07-2209. Epub 2002 Dec 12. PMID: 12480714.
46. Lievens D., Zernecke A., Seijkens T., Soehnlein O., Beckers L., Munnix I.C., Wijnands E., Goossens P., van Kruchten R., Thevissen L., Boon L., Flavell R.A., Noelle R.J., Gerdes N., Biessen E.A., Daemen M.J., Heemskerk J.W., Weber C., Lutgens E. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood., 2010 Nov 18; 116 (20): 4317–4327. doi: 10.1182/blood-2010-01-261206. Epub 2010 Aug 12. PMID: 20705757; PMCID: PMC2993630.
47. Mause S.F., Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res. 2010 Oct 29; 107 (9): 1047–1057. doi: 10.1161/CIRCRESAHA.110.226456. PMID: 21030722.
48. Gawaz M., Brand K., Dickfeld T., Pogatsa-Murray G., Page S., Bogner C., Koch W., Schцmig A., Neumann F. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis, 2000 Jan; 148 (1): 75–85. doi: 10.1016/s0021-9150(99)00241-5. PMID: 10580173.
49. Lindemann S., Tolley N.D., Dixon D.A., McIntyre T.M., Prescott S.M., Zimmerman G.A., Weyrich A.S. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J. Cell Biol., 2001 Aug 6; 154 (3): 485–490. doi: 10.1083/jcb.200105058. PMID: 11489912; PMCID: PMC2196422.
50. Gawaz M., Langer H., May A.E. Platelets in inflammation and atherogenesis. J. Clin. Invest., 2005 Dec; 115 (12): 3378–3384. doi: 10.1172/JCI27196. PMID: 16322783; PMCID: PMC1297269.
51. Lievens D., von Hundelshausen P. Platelets in atherosclerosis. Thromb. Haemost., 2011 Nov; 106 (5): 827– 838. doi: 10.1160/TH11-08-0592. Epub 2011 Oct 20. PMID: 22012554.
52. Willoughby S., Holmes A., Loscalzo J. Platelets and cardiovascular disease. Eur. J. Cardiovasc. Nurs., 2002; 1 (4): 273–288. doi: 10.1016/s1474-5151(02)00038-5
53. Korporaal S.J., Akkerman J.W. Platelet activation by low density lipoprotein and high density lipoprotein. Pathophysiol. Haemost. Thromb., 2006; 35 (3-4): 270–280. doi: 10.1159/000093220
54. Israels S.J., McNicol A , Dean H.J., Cognasse F., Sellers E.A. Markers of platelet activation are increased in adolescents with type 2 diabetes. Diabetes Care., 2014; 37 (8): 2400–2403. doi: 10.2337/dc13-2718
55. van Gils J.M., Zwaginga J.J., Hordijk P.L. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J. Leukoc. Biol., 2009; 85 (2): 195–204. doi: 10.1189/jlb.0708400
56. Kanthi Y., Hyman M.C., Liao H. et al. Flow-dependent expression of ectonucleotide tri(di)phosphohydrolase-1 and suppression of atherosclerosis. J. Clin. Invest., 2015; 125 (8): 3027–3036. doi: 10.1172/JCI79514
57. Davignon J., Ganz P.. Role of endothelial dysfunction in atherosclerosis. Circulation., 2004; 109 (23 suppl 1): III27–III32. doi: 10.1161/01.CIR.0000131515.03336.f8
58. Rondina M.T., Weyrich A.S., Zimmerman G.A. Platelets as cellular effectors of inflammation in vascular diseases. Circ Res., 2013; 112 (11): 1506–1519. doi: 10.1161/CIRCRESAHA.113.300512
59. van Gils J.M., da Costa Martins P.A., Mol A., Hordijk P.L., Zwaginga J.J. Transendothelial migration drives dissociation of plateletmonocyte complexes. Thromb. Haemost., 2008; 100 (2): 271–279. PMID: 18690347.
60. Shim C.Y., Liu Y.N., Atkinson T. et al. Molecular imaging of platelet-endothelial interactions and endothelial von willebrand factor in early and mid-stage atherosclerosis. Circ. Cardiovasc. Imaging., 2015; 8 (7): e002765. doi: 10.1161/CIRCIMAGING.114.002765
61. de Boer H.C., Verseyden C., Ulfman L.H. et al. Fibrin and activated platelets cooperatively guide stem cells to a vascular injury and promote differentiation towards an endothelial cell phenotype. Arterioscler. Thromb. Vasc. Biol., 2006; 26: 1653–1659.
62. Langer H., May A.E., Daub K. et al. Adherent platelets recruit and induce differentiation of murine embryonic endothelial pro genitor cells to mature endothelial cells in vitro. Circ. Res., 2006; 98: e2–10.
63. Lev E.I., Estrov Z., Aboulfatova K. et al. Potential role of activated platelets in homing of human endothelial progenitor cells to subendothelial matrix. Thromb. Haemost., 2006; 96: 498–504.
64. Semenova A.E., Sergienko I.V., Dombrovskij A.L., Rvacheva A.V. Rol’ endotelial’nyh progenitornyh kletok pri ateroskleroze.Ateroskleroz i dislipidemii, 2012; 3. URL: https://cyberleninka.ru/article/n/rol-endotelialnyhprogenitornyh-kletok-pri-ateroskleroze (data obrashcheniya: 25.07.2021). (In Russ.)
65. Pridova S.P., Somonova O.V., Kashiya Sh.R., Obuhova O.A., Sotnikov A.V. Rol’ trombocitov v vospalenii i immunitete. Research’n Practical Medicine Journal, 2018; 3 (5): 40–52. URL: https://cyberleninka.ru/article/n/rol-trombotsitov-v-vospalenii-i-immunitete (data obrashcheniya: 07.03.2021). DOI: 10.17709/2409-2231-2018-5-3-4. (In Russ.)
66. Serebryanaya N.B., Shanin S.N., Fomicheva E.E., Yakuceni P.P. Trombocity kak aktivatory i regulyatory vospalitel’nyh i immunnyh reakcij. CHast’ 1. Osnovnye harakteristiki trombocitov kak vospalitel’nyh kletok. Medicinskaya immunologiya, 2018; 6 (20): 785–796. URL: https://cyberleninka.ru/article/n/trombotsitykak-aktivatory-i-regulyatory-vospalitelnyh-iimmunnyh-reaktsiy-chast-1-osnovnye-harakteristikitrombotsitov-kak (data obrashcheniya: 29.11.2020). doi: 10.15789/1563-0625-2018-6-785-796. (In Russ.)
67. Wang Z.T., Wang Z., Hu Y.W. Possible roles of platelet-derived microparticles in atherosclerosis. Atherosclerosis, 2016 May; 248: 10–16. doi: 10.1016/j.atherosclerosis.2016.03.004. Epub 2016 Mar 4. PMID: 26978582.
68. Suades R., Padrу T., Alonso R., Mata P., Badimon L. High levels of TSP1+/CD142+ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis. Thromb. Haemost., 2015; 114 (6): 1310–1321. doi: 10.1160/TH15-04-0325
69. Xiang B., Zhang G., Ye Sh. et al. Characterization of a novel integrin binding protein, VPS33B, which is important for platelet activation and in vivo. Circulation, 2015; 132: 2334–2344. doi: 10.1161/CIRCULATIONAHA.115.018361
70. Ruggeri Z.M. The role of von Willebrand factor in thrombus formation. Thromb. Res., 2007; 120 (suppl 1): S5–S9. doi: 10.1016/j.thromres.2007.03.011
71. Spiel A.O., Gilbert J.C., Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation, 2008; 117 (11): 1449–1459. doi: 10.1161/CIRCULATIONAHA.107.722827
72. Sonneveld M.A., Kavousi M., Ikram M.A. et al. Low ADAMTS-13 activity and the risk of coronary heart disease: a prospective cohort study: the Rotterdam study. J. Thromb. Haemost., 2016; 14 (11): 2114–2120. doi: 10.1111/jth.13479
73. Theilmeier G., Michiels C., Spaepen E., Vreys I., Collen D., Vermylen J., Hoylaerts M.F. Endothelial von Willebrand factor recruits platelets to atherosclerosisprone sites in response to hypercholesterolemia. Blood., 2002 Jun 15; 99 (12): 4486–4493. doi: 10.1182/blood.v99.12.4486. PMID: 12036879
74. Chung D.W., Chen J., Ling M. et al. High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion. Blood., 2016; 127 (5): 637–645. doi: 10.1182/blood-2014-09-599530
75. Kuijper P.H., Gallardo Torres H.I., Houben L.A., Lammers J.W., Zwaginga J.J., Koenderman L. P-selectin and MAC-1 mediate monocyte rolling and adhesion to ECM-bound platelets under flow conditions. J. Leukoc. Biol., 1998; 64 (4): 467–473. doi: 10.1002/jlb.64.4.467
76. Serebryanaya N.B., Shanin S.N., Fomicheva E.E., Yakuceni P.P. Trombocity kak aktivatory i regulyatory vospalitel’nyh i immunnyh reakcij. CHast’ 1. Osnovnye harakteristiki trombocitov kak vospalitel’nyh kletok. Medicinskaya immunologiya, 2018; 6 (20): 785–796. URL: https://cyberleninka.ru/article/n/trombotsitykak-aktivatory-i-regulyatory-vospalitelnyh-iimmunnyh-reaktsiy-chast-1-osnovnye-harakteristikitrombotsitov-kak (data obrashcheniya: 29.11.2020). doi: 10.15789/1563-0625-2018-6-785-796. (In Russ.)
77. Ahn K.C., Jun A.J., Pawar P. et al. Preferential binding of platelets to monocytes over neutrophils under flow. Biochem. Biophy.s Res. Commun., 2005; 329 (1): 345–355. doi: 10.1016/j.bbrc.2005.01.146
78. Henn V., Slupsky J.R., Grдfe M., Anagnostopoulos I., Fцrster R., Mьller-Berghaus G., Kroczek R.A. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature, 1998 Feb 5; 391 (6667): 591–594. doi: 10.1038/35393. PMID: 9468137.
79. Jenne C.N., Urrutia R., Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. Int. J. Lab. Hematol., 2013 Jun; 35 (3): 254–261. doi: 10.1111/ijlh.12084. PMID: 23590652.
80. Lindemann S., Tolley N.D., Dixon D.A. et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis. J. Cell. Biol., 2001; 154 (3): 485–490. doi: 10.1083/jcb.200105058
81. Huo Y., Ley K.F. Role of platelets in the development of atherosclerosis. Trends Cardiovasc. Med., 2004; 14 (1): 18–22. doi: 10.1016/j.tcm.2003.09.007
82. von Hundelshausen P., Schmitt M.M. Platelets and their chemokines in atherosclerosis-clinical applications. Front Physiol., 2014; 5: 294. doi: 10.3389/fphys.2014.00294
83. Patzelt J., Mueller K., Breuning S., Karathanos A., Schleicher R., Seizer P. et al. Expression of anaphylatoxin receptors on platelets in patients with coronary heart disease. Atherosclerosis, 2015; 238 (2): 289–295. doi: 10.1016/j.atherosclerosis.2014.12.002
84. Seno T., Inoue N., Gao D. et al. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb. Res., 2001; 103 (5): 399–409. doi: 10.1016/s0049-3848(01)003. Vischer UM, Jornot L., Wollheim C.B., Theler J.M. Reactive oxygen intermediates induce regulated secretion of von Willebrand factor from cultured human vascular endothelial cells. Blood., 1995; 85 (11): 3164–3172. PMID: 7756649.
85. Mansurova D.A. Ingibitory P2Y12 receptorov trombocitov pri ostrom koronarnom sindrome: effektivnost’ i bezopasnost’ primeneniya, metody ocenki. Obzor literatury. Nauka i zdravoohranenie, 2018; 3 (20). URL: https://cyberleninka.ru/article/n/ingibitory-p2y12-retseptorov-trombotsitov-pri-ostrom-koronarnomsindrome-effektivnost-i-bezopasnost-primeneniyametody-otsenki-obzor (data obrashcheniya: 25.07.2021). (In Russ.)
86. Tereshchenko S.N., Dzhaiani N.A. Antithrombotic therapy as a basis for prevention of cardiovascular complications. Focus on acetylsalicylic acid. Trudnyy patsient, 2008; 11: 25–32. (In Russ.)
87. Lupanov V.P. The use of aspirin for secondary prevention of coronary heart disease. Russkiy meditsinskiy zhurnal, 2005; 13 (15): 1053–1056. (In Russ.)
88. Ogawa H., Nakayama M., Morimoto T. et al. Lowdose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008; 300 (18): 2134–2141.
89. Belch J., MacCuish A., Campbell I. et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ, 2008; 337: a1840.
90. de Berardis G., Sacco M., Strippoli G.F. et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ, 2009; 339: b4531.
91. McFadyen J.D., Schaff M., Peter K. Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nat. Rev. Cardiol., 2018 Mar; 15 (3): 181–191. doi: 10.1038/nrcardio.2017.206. Epub 2018 Jan 3. PMID: 29297508.
92. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., Buring J., Hennekens C., Kearney P., Meade T., Patrono C., Roncaglioni M.C., Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 2009 May 30; 373 (9678): 1849–1860. doi: 10.1016/S0140-6736(09)60503-1. PMID: 19482214; PMCID: PMC2715005.
93. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002 Jan 12; 324 (7329): 71–86. doi: 10.1136/bmj.324.7329.71. Erratum in: BMJ, 2002 Jan 19; 324 (7330): 141. PMID: 11786451; PMCID: PMC64503.
94. Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C., Prescott E., Storey R.F., Deaton C., Cuisset T., Agewall S., Dickstein K., Edvardsen T., Escaned J., Gersh B.J., Svitil P., Gilard M., Hasdai D., Hatala R., Mahfoud F., Masip J., Muneretto C., Valgimigli M., Achenbach S., Bax J.J.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart. J., 2020 Jan 14; 41 (3): 407–477. doi: 10.1093/eurheartj/ehz425. Erratum in: Eur. Heart. J. 2020 Nov 21; 41 (44): 4242. PMID: 31504439.
95. Zheng S.L., Roddick A.J. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Metaanalysis. JAMA, 2019 Jan 22; 321 (3): 277–287. doi: 10.1001/jama.2018.20578. Erratum in: JAMA, 2019 Jun 11; 321 (22): 2245. PMID: 30667501; PMCID: PMC6439678.
96. ASCEND Study Collaborative Group, Bowman L., Mafham M., Wallendszus K., Stevens W., Buck G., Barton J., Murphy K., Aung T., Haynes R., Cox J., Murawska A., Young A., Lay M., Chen F., Sammons E., Waters E., Adler A., Bodansky J., Farmer A., McPherson R., Neil A., Simpson D., Peto R., Baigent C., Collins R., Parish S., Armitage J. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N. Engl. J. Med., 2018 Oct 18; 379 (16): 1529–1539. doi: 10.1056/NEJMoa1804988. Epub 2018 Aug 26. PMID: 30146931.
97. Gaziano J.M., Brotons C., Coppolecchia R., Cricelli C., Darius H., Gorelick P.B., Howard G., Pearson T.A., Rothwell P.M., Ruilope L.M., Tendera M., Tognoni G; ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, doubleblind, placebo-controlled trial. Lancet, 2018 Sep 22; 392 (10152): 1036–1046. doi: 10.1016/S0140-6736(18)31924-X. Epub 2018 Aug 26. PMID: 30158069; PMCID: PMC7255888.
98. McNeil J.J., Wolfe R., Woods R.L., Tonkin A.M., Donnan G.A., Nelson M.R., Reid C.M., Lockery J.E., Kirpach B., Storey E., Shah R.C., Williamson J.D., Margolis K.L., Ernst M.E., Abhayaratna W.P., Stocks N., Fitzgerald S.M., Orchard S.G., Trevaks R.E., Beilin L.J., Johnston C.I., Ryan J, Radziszewska B., Jelinek M., Malik M., Eaton C.B., Brauer D., Cloud G., Wood E.M., Mahady S.E., Satterfield S., Grimm R., Murray A.M.; ASPREE Investigator Group. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N. Engl. J. Med., 2018 Oct 18; 379 (16): 1509–1518. doi: 10.1056/NEJMoa1805819. Epub 2018 Sep 16. PMID: 30221597; PMCID: PMC6289056.
99. Cyrus T., Sung S., Zhao L., Funk C.D., Tang S., Praticт D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in lowdensity lipoprotein receptor-deficient mice. Circulation, 2002 Sep 3; 106 (10): 1282–1287. doi: 10.1161/01.cir.0000027816.54430.96. PMID: 12208806.
100. Tous M., Ferrй N., Vilella E., Riu F., Camps J., Joven J. Aspirin attenuates the initiation but not the progression of atherosclerosis in apolipoprotein E-deficient mice fed a high-fat, high-cholesterol diet. Basic Clin. Pharmacol. Toxicol., 2004 Jul; 95 (1): 15–19. doi: 10.1111/j.1742-7843.2004.pto950104.x.PMID: 15245571.
101. Afek A., Kogan E., Maysel-Auslender S., Mor A., Regev E., Rubinstein A., Keren G., George J. Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice. Microvasc. Res., 2009 May; 77 (3): 364–369. doi: 10.1016/j.mvr.2009.01.009. Epub 2009 Jan 31. PMID: 19323972.
102. Li M., Zhang Y., Ren H., Zhang Y., Zhu X. Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model. Atherosclerosis, 2007 Oct; 194 (2): 348–356. doi: 10.1016/j.atherosclerosis.2006.11.006. Epub 2006 Dec 6. PMID: 17156785.
103. Yamamoto Y., Yamashita T., Kitagawa F., Sakamoto K., Giddings J.C., Yamamoto J. The effect of the long term aspirin administration on the progress of atherosclerosis in apoE-/- LDLR-/- double knockout mouse. Thromb. Res., 2010 Mar; 125 (3): 246–252. doi: 10.1016/j.thromres.2009.11.008. Epub 2009 Dec 16. PMID: 20005558.
104. Heim C., Gebhardt J., Ramsperger-Gleixner M., Jacobi J., Weyand M., Ensminger S.M. Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo. Heart Vessels., 2016 May; 31 (5): 783–794. doi: 10.1007/s00380-015-0696-7. Epub 2015 Jun 11. PMID: 26062773.